If you grew up outside the United States, there is a good chance you received the BCG vaccine as a child. That single fact used to complicate your immigration medical exam, because the old tuberculin skin test could not tell the difference between a reaction caused by BCG and a reaction caused by a real tuberculosis infection. Understanding why that happened, and why your civil surgeon now uses a blood test instead, makes the TB portion of the I-693 far less confusing.
This is not a theoretical footnote. Bacille Calmette-Guerin, or BCG, is one of the most widely administered vaccines in the world outside the U.S., given routinely in many countries as protection against severe childhood tuberculosis. Applicants coming from those countries make up a large share of the people sitting in a civil surgeon’s office every week, which is exactly why this issue shaped how USCIS structured its current TB testing requirement.
How BCG Confuses the Traditional Skin Test
The tuberculin skin test, also called the PPD or Mantoux test, works by injecting a small amount of purified protein derived from Mycobacterium tuberculosis under the skin and measuring the immune reaction a few days later. The problem is that the BCG vaccine is made from a weakened, related bacterium, Mycobacterium bovis, which shares several antigens with the bacterium that causes tuberculosis in humans. A vaccinated immune system can respond to the skin test as though it recognizes real TB exposure, producing a raised, reactive bump even when no infection is present.
The practical consequence is that a positive skin test on its own cannot distinguish three very different situations: a person with latent TB infection, a person with active TB disease, and a person who simply received a routine childhood vaccine years earlier. There is no reliable way to separate a BCG-driven reaction from a true infection using the skin test alone, which made it a poor screening tool for a population where prior BCG vaccination is common rather than rare.
Why USCIS Moved Away From the Skin Test
Because of that unreliability, USCIS no longer accepts the tuberculin skin test as the TB screening method for Form I-693 medical exams. Civil surgeons are instead required to use an interferon-gamma release assay, or IGRA, blood test for every applicant age two and older. The two IGRA tests currently accepted for the immigration exam are QuantiFERON-TB Gold Plus and T-SPOT.TB. Both are FDA-approved laboratory blood tests rather than the older injection-and-read skin exam, and both are specified in the CDC’s Technical Instructions for Civil Surgeons, which govern exactly how a civil surgeon must document TB status on the I-693.
This is a case where the exam requirement exists precisely because of a known weakness in the older method. USCIS did not add the blood-test requirement to make the process more expensive or more complicated for applicants; it changed the standard because the skin test was producing an unacceptable number of false positives in a globally diverse applicant pool, many of whom carry a BCG vaccination history from childhood.
Why the IGRA Blood Test Solves the BCG Problem
An IGRA test works on a fundamentally different principle than the skin test. Instead of injecting a broad protein derivative and watching for a general immune reaction, the blood test exposes a sample of your blood to proteins that are specific to Mycobacterium tuberculosis and are not present in the BCG vaccine strain. If your immune cells were never actually exposed to tuberculosis, they simply do not react to those specific proteins, regardless of whether you received BCG as a child. That is the entire reason the blood test replaced the skin test for immigration purposes: BCG vaccination does not produce a false positive on an IGRA, so the result reflects genuine TB exposure rather than vaccine history.
| Feature | PPD Skin Test (TST) | IGRA Blood Test |
|---|---|---|
| Accepted for I-693 exams | No, discontinued | Yes, required for applicants 2 and older |
| Affected by prior BCG vaccination | Yes, can cause false positives | No, BCG does not trigger a reaction |
| Method | Injection under the skin, read 48 to 72 hours later | Single blood draw, lab-processed |
| Return visit required to read result | Yes | No, results come from the lab sample |
| Approved test names for I-693 | Not applicable | QuantiFERON-TB Gold Plus, T-SPOT.TB |
What Happens After a Positive IGRA Result
A positive IGRA does not automatically mean you have active tuberculosis disease, and it does not mean your application is denied. It means your civil surgeon is required to follow up with a chest X-ray to rule out active TB. If the X-ray comes back clear, the positive blood test most likely reflects a latent TB infection, meaning the bacteria are present in an inactive, non-contagious form. If the X-ray shows findings consistent with active disease, further evaluation is required, which can include sputum testing, before the civil surgeon can complete your I-693. Each of these steps follows the CDC’s Technical Instructions, so the sequence is the same regardless of which civil surgeon you see.
What This Means If You Were Vaccinated With BCG
If you know you received the BCG vaccine growing up, it is worth mentioning to your civil surgeon’s office before your appointment, mainly so the visit goes smoothly, since the blood-draw requirement will apply regardless. The practical upside is that you no longer have to worry about a routine childhood vaccination producing a confusing or inaccurate result on a form that matters this much to your case. The blood test was adopted specifically to remove that uncertainty, replacing a decades-old method that could not separate a vaccine reaction from a real infection with one that can.
Understanding the reasoning behind the TB testing requirement, rather than just complying with it, is part of walking into your immigration medical exam prepared. A BCG vaccination in your past is common, expected, and no longer a source of confusion once the exam moves to a blood-based IGRA test designed to screen past it.